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Background:  The present study investigated the efficacy and safety of vildagliptin-metformin treatment compared to those of 
glimepiride-metformin treatment for type 2 diabetes.
Methods: In a randomized, open-label, comparative study, 106 patients with type 2 diabetes were enrolled. The primary end-
point was a reduction in HbA1c from baseline and secondary endpoints included fasting plasma glucose (FPG) or 2-hour post-
prandial glucose (2h-PPG) reduction from baseline, as well as HbA1c responder rate and HbA1c reduction according to baseline 
HbA1c category. 
Results: Comparable HbA1c reduction was observed with a mean±standard deviation change from baseline to the 32-week 
endpoint of -0.94±1.15% in the vildagliptin group and -1.00±1.32% in the glimepiride group. A similar reduction in 2h-PPG 
(vildagliptin group 3.53±4.11 mmol/L vs. the glimepiride group 3.72±4.17 mmol/L) was demonstrated, and the decrements in 
FPG (vildagliptin group 1.54±2.41 mmol/L vs. glimepiride group 2.16±2.51 mmol/L) were not different between groups. The 
proportion of patients who achieved an HbA1c less than 7% at week 32 was 50.1% in the vildagliptin group and 56.0% in the 
glimepiride group. An average body weight gain of 2.53±1.21 kg in the glimepiride group was observed in contrast with the 
0.23±0.69 kg weight gain noted in the vildagliptin group. A 10-fold lower incidence of hypoglycemia was demonstrated in the 
vildagliptin group, in addition to an absence of severe hypoglycemia.
Conclusion: Vildagliptin-metformin treatment provided blood glucose control efficacy comparable to that of glimepiride-met-
formin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain. 
Keywords:  Diabetes mellitus, type 2; Glimepiride; Metformin; Vildagliptin
Corresponding author:  Tae Keun Oh
Department of Internal Medicine, Chungbuk National University Hospital, 
410 Gaesin-dong, Heungdeok-gu, Cheongju 361-711, Korea
E–mail: tgohkjs@chungbuk.ac.kr
Received: Jan. 11, 2011; Accepted: Jun. 9, 2011
INTRODUCTION 
Several clinical studies have demonstrated that tight glycemic 
control is necessary to prevent diabetic complications in type 
2 as well as type 1 diabetic patients [1-4]. 
  However, tight glycemic control is definitely associated with 
frequent hypoglycemic attacks, and several papers recently re-
ported that aggressive glucose control did not produce any 
cardiovascular (CV) benefits but rather induced severe hypo-
glycemia and increased mortality in type 2 diabetes mellitus 
patients [5-7]. Many type 2 diabetic patients require more 
than two oral hypoglycemic agents because treatment with a 
single agent often results in sub-optimal outcomes. Combina-
tion therapy early in diabetes management would be a proper 
approach considering the complex pathophysiologic defects 
associated with diabetes.
  Recently, several new classes of oral hypoglycemic agents 
have been introduced [8-10]. Vildagliptin is an oral and highly 
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selective dipeptidyl peptidase-4 (DPP-4) inhibitor which pre-
vents the rapid degradation of endogenous glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic peptide 
(GIP) and increases the levels of the intact, active form of en-
dogenous GLP-1. Vildagliptin improves glycemic control in 
type 2 diabetic patients either as a monotherapy or adminis-
tered in combination with metformin, sulfonylurea, thiazoli-
dinedione or insulin [11-14]. Improvements in glycemic con-
trol are mediated primarily by increased insulin secretion and 
the suppression of glucagon secretion. Both of these effects 
depend on plasma glucose concentration, indicating that insu-
lin secretion is suppressed and glucagon secretion is stimulat-
ed under low-blood glucose conditions. Vildagliptin has not 
demonstrated any effects on body weight and does not evoke 
severe hypoglycemia. 
  Sulfonylurea is a potent oral hypoglycemic agent and is 
commonly prescribed as a monotherapy or as a component of 
combination therapy for the treatment of type 2 diabetic pa-
tients over 60 years of age [15,16]. Although sulfonylurea is 
well-known as being effective in lowering blood glucose, it 
also induces body weight gain and severe hypoglycemia. 
  In the present study, the efficacy and safety of vildagliptin-
metformin treatment compared to those of glimepiride-met-
formin treatment were evaluated over 32 weeks in type 2 dia-
betic patients. 
METHODS
Subjects
The present study was randomized, open-label and compara-
tive. Patients who attended the outpatient diabetic clinic of 
Chungbuk National University Hospital were included, and 
exclusion criteria were evaluated during screening (week -2, 
visit 1). Type 2 diabetic patients with HbA1c levels greater than 
7.0% who were naïve or were receiving monotherapy with oral 
hypoglycemic agents such as glimepiride (2 to 4 mg) or met-
formin (500 to 1,000 mg) for less than six months prior to the 
visit were eligible to participate in the present study. All the 
patients who received previous medications had to undergo a 
wash-out period of at least two weeks. Patients with a history 
of diabetic ketoacidosis, clinically significant liver or renal dis-
ease, congestive heart failure requiring pharmacological treat-
ment, coronary artery percutaneous intervention or unstable 
angina within the past six months, and those over 80 years of 
age were excluded from the present study. Any of the follow-
ing laboratory abnormalities at screening also precluded par-
ticipation: serum creatinine >133 μmol/L, alanine amino-
transferase or aspartate aminotransferase >3 times the upper 
limit of normal and total bilirubin >34 μmol/L. 
  All patients provided written informed consent prior to 
participation in the present study. The study protocol was re-
viewed and approved by the Institutional Review Board of 
Chungbuk National University Hospital. Eligible patients were 
assigned randomly at a 1:1 ratio at baseline (day 0) to receive 
either 50 mg of vildagliptin twice daily or 2 mg glimepiride 
twice daily in addition to 500 mg of metformin twice daily for 
32 weeks. During the follow-up period, glimepiride-metfor-
min treatment was down-titrated in cases of recurrent hypo-
glycemia. 
Efficacy assessments 
Assessments included overnight fasting plasma glucose (FPG), 
2-hour postprandial glucose (2-h PPG), HbA1c, fasting insu-
lin, fasting C-peptide, body weight, and vital signs at each 
scheduled visit (week 0, 4, 12, 24, and 32). Homeostasis model 
assessment of β-cell (HOMA-β) and homeostasis model as-
sessment of insulin resistance (HOMA-IR) were evaluated to 
assess pancreatic β-cell function and changes in insulin resis-
tance, respectively. The primary efficacy endpoint was a change 
in HbA1c from baseline at week 32. Secondary efficacy end-
points included FPG or 2-h PPG reduction from baseline, as 
well as HbA1c responder rate and HbA1c reduction according 
to baseline HbA1c category. All adverse events and tolerability 
values were monitored throughout the study. Hypoglycemia 
was defined as a finger stick glucose concentration of less than 
3.9 mmol/L without loss of consciousness. Severe hypoglyce-
mia was defined in the patients with transient dysfunction of 
the central nervous system who were unable to treat them-
selves. 
Statistical analysis
Vildagliptin was regarded as comparable to glimepiride if the 
upper boundary of the two-sided 90% confidence interval 
around the between-group difference in HbA1c was less than 
the predefined margin, δ=0.3%. The data were expressed as 
mean±standard deviation. All statistical tests were performed 
using the SPSS version 12.0 software package (SPSS Inc., Chi-
cago, IL, USA). The means and frequencies of variables were 
evaluated using Student’s t-test and the χ
2 test, respectively. All 
P values less than 0.05 were regarded as statistically significant.531
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RESULTS
Clinical characteristics 
The present study randomly enrolled 106 patients (52 patients 
in glimepiride-metformin group and 54 patients in vildagliptin-
metformin group). One patient in the glimepiride-metformin 
group and three patients in the vildagliptin-metformin group 
were eliminated from the study in the first four weeks due to 
recurrent hypoglycemia or intolerable gastrointestinal (GI) 
trouble, respectively. Finally, 51 patients (94.4%) in the vilda-
gliptin-metformin group and 51 patients (98%) in the 
glimepiride-metformin group completed 32 weeks of treat-
ment. The patients who discontinued medication due to adverse 
events were not included in the final analysis. The final analyzed 
patients consisted of 66 males and 36 females, with a mean age 
of 54 years and an average duration of diabetes of 5.9 years. 
  The groups were balanced at baseline with a mean HbA1c 
of 8.01 vs. 8.13% and FPG of 8.78 vs. 9.34 mmol/L. Table 1 
summarizes the baseline demographic and clinical character-
istics of the patients. 
Efficacy of glucose control 
Mean FPG±standard deviation was decreased from 8.78± 
2.32 mmol/L at baseline to 7.24±1.64 mmol/L at week 32 in 
the vildagliptin-metformin group and from 9.34±2.14 mmol/
L to 7.18±1.91 mmol/L in the glimepiride-metformin group. 
The reductions in FPG level were comparable between treat-
ment groups (vildagliptin-metformin 1.54±2.41 mmol/L vs. 
glimepiride-metformin 2.16±2.51 mmol/L, P=0.508; Fig. 1A). 
Both treatments showed similar efficacy with regard to the 2h-
PPG level; the reduction was 3.53±4.11 mmol/L (from 13.67± 
3.59 to 10.14±3.46) in the vildagliptin-metformin group and 
3.72±4.17 mmol/L (from 14.44±2.22 to 10.72±3.36, P=0.950) 
in the glimepiride-metformin group (Fig. 1A). 
  The mean HbA1c was decreased from 8.01 to 7.07 (1.21% 
to 0.81%) in the vildagliptin-metformin group and from 8.13 
to 7.13 (0.86% to 0.81%) in the glimepiride-metformin group; 
the decrements in HbA1c were also comparable between 
groups (vildagliptin-metformin 1.15 (-0.94%) and glimepiri-
de-metformin 1.32 (-1.00%), P=0.855; Fig. 1B). 
  At week 12, when HbA1c was measured first after the initia-
tion of the study, HbA1c was significantly decreased from 
baseline; the decrements in HbA1c did not differ appreciably 
between the treatment groups. Additionally, HbA1c remained 
stable until the endpoint at week 32 (Fig. 1C).
  The proportions of patients who achieved an HbA1c less 
Table 1.  Demographics and baseline characteristics of patients 
Characteristic
Vildagliptin+ 
Metformin  
(n=51)
Glimepiride+ 
Metformin  
(n=51)
Age, yr 53.51±10.41 55.38±10.98
Sex, n (%)
Male 35 (68.6) 31 (60.8)
Female  16 (31.4) 20 (39.2)
BMI, kg/m
2 22.69±7.75 23.07±4.24
Duration of diabetes, yr 5.89±1.64 5.92±1.74
FPG, mmol/L  8.78±2.32 9.34±2.14
2h-PPG, mmol/L  13.67±3.59 14.44±2.22
HbA1C, % 8.01±1.20 8.13±0.86
Insulin, pmol/L  95.21±48.93 98.51±79.21
C-peptide, nmol/L  1.01±0.70 0.99±0.67
HOMA-β 44.31±20.93 41.90±20.93
HOMA-IR 5.11±2.63 5.16±6.51
BMI, body mass index, FPG, fasting plasma glucose; 2h-PPG, 2-hour 
post-prandial glucose; HOMA-β, Homeostasis model assessment of 
β-cell; HOMA-IR, homeostasis model assessment of insulin resis-
tance. 
Fig. 1.  (A) Mean fasting plasma glucose (FPG) and 2-hour 
post-prandial glucose (2h-PPG) reduction in vildagliptin or 
glimepiride treatment. (B) Decrement of HbA1c on the week 
32 end-point in vildagliptin or glimepiride treatment. (C) Mean 
HbA1c changes during 32 weeks in vildagliptin or glimepiride 
treatment. 
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than 7% at the endpoint were also similar in the vildagliptin-
metformin (50.1%) and glimepiride-metformin (56%) treat-
ment group. In the subgroup analysis of baseline HbA1c cate-
gory, both treatments showed similar HbA1c reduction effi-
ciencies in all categories: greater reductions in HbA1c were 
noted in patients with higher baseline HbA1c concentrations 
(Fig. 2). The difference between the responders vs. non-re-
sponders was assessed, but no differences were observed be-
tween the two groups, with the exception of glucose and HbA1c 
levels.
  Baseline fasting insulin, C-peptide, HOMA-β, and HOMA-
IR were similar in the vildagliptin-metformin and glimepiride-
metformin groups. During the treatment period, the changes 
in HOMA-β and HOMA-IR were comparable between the 
two groups (Table 2). 
Changes in body weight 
Mean body weight at baseline was 66.2±7.8 kg and 69.7±10.2 
kg in the glimepiride-metformin and vildagliptin-metformin 
groups, respectively. At week 32, significant weight gain was 
observed in the glimepiride-metformin group (2.35±1.21 kg) 
compared to that in the vildagliptin-metformin group (0.23± 
0.69 kg) (P<0.05). 
Tolerability 
The overall incidence of hypoglycemia was 10-fold higher in 
patients treated with the glimepiride-metformin combination 
(ten patients vs. one patient in the vildagliptin-metformin 
group, P<0.05; Table 3) even though one patient in the 
glimepiride-metformin group was excluded from the study 
within the first four weeks of enrollment due to severe hypo-
glycemia. A majority of the patients had hypoglycemia that 
did not require medical assistance, although one patient who 
received glimepiride-metformin required medical assistance 
due to loss of consciousness. No severe hypoglycemia occurred 
in any of the patients taking vildagliptin-metformin. 
  The frequent adverse events in the vildagliptin-metformin 
group were GI events such as nausea, vomiting and diarrhea. 
Three patients in the vildagliptin-metformin group discontin-
ued taking the medication due to intolerable GI problems 
within the first four weeks (Table 3). No meaningful changes 
were observed in the hematologic, biochemical or urinary 
analysis of vital signs, nor were any significant increases in liv-
er function or muscle enzyme values observed in either group. 
Fig. 2.  Mean HbA1c reduction according to the baseline 
HbA1c category.
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  HbA1c<8 %  8≤HbA1c<9 %  HbA1c≥9 %
0
-1
-2
-3
-4
Table 2.  Baseline and post-treatment mean insulin, C-peptide, HOMA-β, and HOMA-IR
Variable 0 week 12 weeks 24 weeks 32 weeks
Insulin, pmol/L 
Vildagliptin+Metformin 13.27±6.87 15.54±9.76 16.67±11.24 14.02±9.54
Glimepiride+Metformin 13.74±7.15 15.96±10.54 17.54±12.54 14.28±10.54
C-peptide, nmol/L 
Vildagliptin+Metformin 3.03±2.09 3.34±2.04 4.04±2.35 4.54±2.15
Glimepiride+Metformin 2.99±2.08 3.98±2.98 3.95±2.99 4.15±2.99
HOMA-β
Vildagliptin+Metformin 44.31±20.93 45.49±21.73 42.31±20.41 47.28±22.36
Glimepiride+Metformin 41.90±20.93 45.51±20.84 43.01±24.21 48.04±23.64
HOMA-IR
Vildagliptin+Metformin 5.11±2.63 4.16±2.26 4.69±2.99  4.53±3.22
Glimepiride+Metformin 5.16±6.51  5.01±2.65 5.14±2.21 4.98±2.21
HOMA-β, Homeostasis model assessment of β-cell; HOMA-IR, homeostasis model assessment of insulin resistance.533
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DISCUSSION 
In the present study, the vildagliptin-metformin treatment 
showed an HbA1c reduction comparable to that of the glimepiri-
de-metformin treatment over a 32-week period. The propor-
tions of patients who achieved an HbA1c of less than 7.0% and 
HbA1c reduction according to the baseline HbA1c category 
were similar between treatments. Furthermore, vildagliptin-
metformin treatment did not evoke weight gain and provided 
definite advantages in terms of hypoglycemia incidence reduc-
tion. 
  Regarding safety, the vildagliptin-metformin treatment had 
a favorable hypoglycemic profile: a 10-fold lower incidence of 
hypoglycemia, with no severe hypoglycemia observed. Several 
papers have recently been published regarding the association 
between hypoglycemia and adverse clinical outcome [9,11]. In 
the Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) trial, intensive blood glucose control did not produce 
any benefits with regard to CV events but did provoke unan-
ticipated excess mortality: 19 of the 41 deaths were attributed 
to unexpected CV disease, which may have been related to se-
vere hypoglycemia [5]. 
  In another trial, the Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE), severe hypoglycemia was strongly 
associated with increased risks of adverse clinical outcomes. 
During the follow-up period, severe hypoglycemia was associ-
ated with a significant increase in the adjusted risks of major 
macrovascular events (hazard ratio [HR], 2.88), major micro-
vascular events (HR, 1.81), death from a CV cause (HR, 2.68), 
and death from any cause (HR, 2.69; P<0.001 for all compari-
sons) [17]. The results of these analyses showed that the previ-
ous severe hypoglycemia occurrence was likely to constitute a 
marker of vulnerability to a primary CV event or death re-
gardless of the treatment arm. Considering the potential CV 
risk associated with severe hypoglycemia, the use of medica-
tions associated with a low risk of hypoglycemia for the con-
trol and management of blood glucose in patients with type 2 
diabetes would be prudent. Three patients in the vildagliptin-
metformin treatment group discontinued taking medication 
in the first four weeks due to intolerable GI side effects, but 
these effects were likely attributed to metformin rather than 
vildagliptin since the GI side effects in the patients disappeared 
after vildagliptin monotherapy. Several patients in both treat-
ments complained of GI side effects such as metallic taste, re-
duced appetite, or dyspepsia. However, the majority of GI 
symptoms disappeared over time in both treatment groups, 
and the patients who complained of GI troubles in the initial 
period of treatment eventually grew tolerant of the medica-
tions. DPP-4 inhibitors increase endogenous GLP-1 levels via 
inhibition of the DPP-4 enzyme. Increased GLP-1 can physio-
logically inhibit the satiety center in the brain, reduce appetite, 
and delay stomach emptying [18]. Vildagliptin-metformin 
treatment has a greater potential to evoke GI side effects com-
pared to glimepiride-metformin treatment in terms of the rel-
evant pharmacological mechanisms, although previous stud-
ies did not show any further increase in GI side effects between 
metformin monotherapy and metformin-vildagliptin combi-
nation therapy [19,20]. Although there is no current obvious 
explanation why only patients in the vildagliptin-metformin 
treatment group experienced intolerable GI trouble, initiating 
vildagliptin treatment with a low-dose of metformin in order 
to ameliorate the GI side effects is advisable.
  In the present study, changes in body weight differed be-
tween the treatment groups. At 32 weeks, body weight was 
unchanged in the vildagliptin-metformin treatment group, 
whereas the patients treated with glimepiride-metformin evi-
denced weight increase (2.35 kg) relative to baseline. The re-
sults were consistent with findings reported in other studies 
involving vildagliptin or sitagliptin in combination with met-
formin [21,22]. In another study comparing the efficacies of 
Table 3.  Safety summary 
Variable
Vildagliptin 
(n=51)
Glimepiride 
(n=51)
One or more AE 5 10
SAEs 0 1
Discontinuations due to AE 3  1
Hypoglycemia (patient number) 1 10 
Overall gastrointestinal AE 4 0
Selected gastrointestinal AE
Abdominal pain 0 0
Nausea 1 0
Vomiting 2 0
Diarrhea  1 0
The patients who discontinued medication due to AE were not con-
tained in final analysis.
AE, adverse event; SAE, serious adverse event, which means to need 
medical assistance.534
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vildagliptin and glimepiride in combination with metformin, 
Matthews et al. [22] reported results similar to the present 
study. In the 52-week follow-up period in that previous study, 
an HbA1c reduction of -0.44% was reported in the vildagliptin 
group and a -0.53% reduction in the glimepiride group. DPP-
4 inhibitors have been shown to improve glycemic control and 
measures of pancreatic ß-cell function in clinical trials in the 
Asian population, including patients from China, India, and 
Korea [23]. Deterioration in the early insulin responses is fre-
quently observed in patients with type 2 diabetes, particularly 
in the Asian population. DPP-4 inhibitors improved pancreat-
ic ß-cell dysfunction and may be associated with more im-
proved responses in Asian than in Caucasian patients [24]. 
  In terms of safety profiles, decreased weight gain and low 
incidence of hypoglycemia were also observed in the vilda-
gliptin treatment group [23]. In the extended two-year obser-
vation period in the previous study, the vildagliptin-metfor-
min combination treatment group still evidenced similar glu-
cose control and better safety profiles [22]. When considering 
the different patient characteristics, the body mass indexes of 
the study populations were different between our study and 
that of Dejager (22 to 23 vs. 31 to 32, respectively); therefore, 
the vildagliptin-metformin combination treatment can be 
considered as comparable to the glimepiride-metformin com-
bination treatment in both non-obese and obese type 2 dia-
betic patients. A previous one-year study [19] comparing the 
efficacies of sitagliptin or glipizide in combination with met-
formin showed similar results to those observed in the present 
study, demonstrating comparable efficacy, less weight gain and 
lower risk of hypoglycemia with sitagliptin. Collectively, the 
results indicate that DPP-4 inhibitors added to metformin 
may represent a more effective combination in type 2 diabetic 
patients with unfavorable glucose control in monotherapy. 
  In terms of the incidence of CV events in association with 
vildagliptin or glimepiride treatments, Dejager’s study report-
ed that fewer patients treated with a vildagliptin-metformin 
combination after 52 weeks of treatment experienced CV events 
confirmed by the adjudication committee (0.9%) than were 
observed in the patients treated with a glimepiride-metformin 
combination (1.6%) [22,23,25]. Although additional long-
term studies of CV events in association with DPP-4 inhibitors 
are warranted, the findings from the present study suggest that 
a vildagliptin-metformin combination treatment may consti-
tute an effective alternative therapeutic option for type 2 dia-
betic patients, with relative confidence regarding the initiation 
of CV disease. 
  Although the present study had several limitations in terms 
of the small number of participants and its status as an open-
label study without blinding, the results demonstrated that 
vildagliptin-metformin combination treatment offered com-
parable efficacy in terms of HbA1c reduction, no weight gain, 
and a lower risk of hypoglycemia in type 2 diabetic patients 
with unfavorable blood glucose control. When safety is con-
sidered along with effectiveness, the vildagliptin-metformin 
combination treatment may constitute a better therapeutic op-
tion than does the glimepiride-metformin combination treat-
ment. 
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